Table 2.
Patients’ Characteristics (N = 89).
| N (%) | |
|---|---|
| Gender | |
| Female | 39 (43.8) |
| Male | 50 (56.2) |
| Type of leukemia | |
| ALL | 68 (76.4) |
| AML | 21 (23.6) |
| Age at diagnosis (Mean ± SD), y | 8.5 ± 5.1 |
| CNS radiation | 12 (13.5) |
| HSCT* | 44 (49.4) |
| History of relapse | 25 (28.1) |
| Follow-up duration from diagnosis (Mean ± SD), y | 13.8 ± 4.9 |
| Growth hormone deficiency | |
| No | 84 (94) |
| Yes without treatment | 0 (0) |
| Yes with treatment | 5 (6) |
| Hypogonadism | |
| No | 59 (66.3) |
| Yes without treatment | 4 (4.5) |
| Yes with treatment | 26 (29.2) |
| Metabolic syndrome (data for 77 patients) | 5 (6.5) |
| Corticosteroids | 66 (74) |
| Cumulative dose† (Mean ± SD) | 6118.2 ± 3197.9 |
| Interval from diagnosis to first scan (Mean ± SD), y | 7.0 ± 4.7 |
| Interval from diagnosis to second scan (Mean ± SD), y | 11.7 ± 5.2 |
| Interval between both scans | |
| Mean ± SD, y | 4.8 ± 2.6 |
| Median (minimum–maximum) | 3.8 (1.30–12.75) |
ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; CNS = central nervous system; HSCT = hematopoietic stem cell transplantation; SD = standard deviation.
*Of 44, 37 patients had total body irradiation.
†Dose of prednisone + dose of dexamethasone X 6.67 (in mg/m2).